Teleflex (TFX) to Post Quarterly Earnings on Thursday

Teleflex (NYSE:TFX) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Teleflex to post earnings of $1.28 per share and revenue of $559.5890 million for the quarter. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, May 7th. The medical technology company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.18. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The business had revenue of $548.30 million for the quarter, compared to analyst estimates of $536.91 million. During the same period last year, the firm earned $1.44 earnings per share. Teleflex’s revenue for the quarter was up 32.3% compared to the same quarter last year. On average, analysts expect Teleflex to post $7 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Teleflex Stock Up 0.3%

NYSE TFX opened at $140.06 on Wednesday. The company has a current ratio of 2.55, a quick ratio of 2.03 and a debt-to-equity ratio of 0.82. The company has a market cap of $6.20 billion, a price-to-earnings ratio of -6.14, a PEG ratio of 1.04 and a beta of 0.81. The company has a 50 day moving average of $131.27 and a 200-day moving average of $121.97. Teleflex has a 1-year low of $100.18 and a 1-year high of $144.19.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Monday, May 25th were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, May 22nd. This represents a $1.36 annualized dividend and a yield of 1.0%. Teleflex’s dividend payout ratio is currently -5.96%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of TFX. Empowered Funds LLC boosted its position in shares of Teleflex by 15.8% during the 1st quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company’s stock valued at $233,000 after purchasing an additional 230 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Teleflex by 42.6% during the first quarter. Jane Street Group LLC now owns 6,343 shares of the medical technology company’s stock valued at $877,000 after purchasing an additional 1,895 shares in the last quarter. American Century Companies Inc. grew its position in Teleflex by 32.7% in the 2nd quarter. American Century Companies Inc. now owns 13,640 shares of the medical technology company’s stock worth $1,614,000 after purchasing an additional 3,360 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Teleflex by 1.2% in the second quarter. Invesco Ltd. now owns 135,516 shares of the medical technology company’s stock valued at $16,040,000 after acquiring an additional 1,659 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of Teleflex by 108.1% during the second quarter. EverSource Wealth Advisors LLC now owns 1,003 shares of the medical technology company’s stock valued at $119,000 after acquiring an additional 521 shares during the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Wells Fargo & Company boosted their target price on shares of Teleflex from $130.00 to $138.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Needham & Company LLC upped their target price on Teleflex from $147.00 to $159.00 and gave the stock a “buy” rating in a research note on Friday. BMO Capital Markets initiated coverage on Teleflex in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $159.00 price target on the stock. Piper Sandler upgraded Teleflex from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $140.00 to $160.00 in a research report on Monday, June 8th. Finally, Bank of America upgraded Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 target price on the stock in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Teleflex presently has a consensus rating of “Hold” and an average target price of $148.90.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.